Logo

Can Japan hold on to its ‘indispensable’ companies? - Financial Times

Last Updated: 23.06.2025 01:32

Can Japan hold on to its ‘indispensable’ companies? - Financial Times

Access to eight surprising articles a day, hand-picked by FT editors. For seamless reading, access … [+73 chars]

Join FT Edit

Only $49 a year

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer - Novartis

Get 2 months free with an annual subscription at was $59.88now $49.